Live video webcast on Wednesday, January 18th at
10:00 AM ET
HOUSTON, January 5,
2023 /PRNewswire/ -- CNS Pharmaceuticals,
Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
biopharmaceutical company specializing in the development of novel
treatments for primary and metastatic cancers in the brain and
central nervous system, today announced that John Climaco, Chief Executive Officer of CNS
Pharmaceuticals will present at the Virtual Investor 2023 Companies
to Watch Event on Wednesday, January 18,
2023 at 10:00 AM ET.
A live video webcast of the presentation will be available
on the Events page of the Investors section of the
Company's website (cnspharma.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-2023-companies-to-watch-event-301714427.html
SOURCE CNS Pharmaceuticals, Inc.